Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
MKTW$19.58+0.75(+3.98%)MarketWise, Inc. Declares Quarterly Dividend on Class A Common Stock of $0.45 Per Share[9:00:14 AM ET]UFPI$80.93-0.30(-0.37%)UFP Packaging Expands Gulf Coast Pallet Network with Acquisition of Apache Products UFP Packaging, a division of UFP Industries (Nasdaq: UFPI), announced this week the acquisition of Apache Products, Inc., a pallet producer based in...[9:00:00 AM ET]THFF$77.70+1.24(+1.62%)First Financial Corporation Reports Third Quarter Results[9:00:00 AM ET]FTNT$181.84-1.49(-0.81%)Fortinet Expands Unified SASE to Simplify Microbranch Security[9:00:00 AM ET]VELO$6.61+0.12(+1.85%)Velo3D to Announce Third Quarter 2026 Results on November 10, 2026 Velo3D, Inc. (Nasdaq: VELO), a leading metal additive manufacturing technology company, today announced that it will release its third quarter 2026...[9:00:00 AM ET]CPB$20.53-0.10(-0.48%)Campbell's® Marks Five Years of Sides Season™ with Its Annual State of the Sides Report Campbell's officially kicked off Sides Season™ with the release of its 2026 State of the Sides Report. Now in its fifth year, the report offers a...[9:00:00 AM ET]TENB$47.55-0.66(-1.37%)Tenable Selected by Atos to Power Continuous Threat Exposure Management Program[9:00:00 AM ET]PLUR$1.24+0.12(+10.69%)Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments[9:00:00 AM ET]ATYR$0.12-0.03(-22.10%)aTyr Pharma Announces One-for-40 Reverse Stock Split[9:00:00 AM ET]KD$14.70+0.02(+0.14%)Kyndryl Opens New Cyber Defense Operations Center in Paris Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, today unveiled a new Cyber Defense Operations Center in...[9:00:00 AM ET]DVN$51.27-0.37(-0.72%)NEQ Operating Strengthens Leadership Team to Support Next Phase of Growth[9:00:00 AM ET]SSBI$12.00-0.10(-0.83%)Summit State Bank Reports Third Quarter 2026 Financial Results[9:00:00 AM ET]QVCG$7.28-0.85(-10.46%)HSN Announces Michelle Buteau, Christie Brinkley, Curtis Stone and Dr. Paul Nassif as 'Holiday Helpers' for the Season HSN®, a leader in live social shopping and video storytelling, is making the holiday season more joyful and effortless with the launch of HSN Holiday ...[9:00:00 AM ET]

NGNE · NASDAQ

Neurogene Inc.

$23.57 0.00 (0.00%)

Company overview

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidates include NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome, and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$372M
Employees
107
Headquarters
New York City, NY
Website
neurogene.com
CEO
Rachel L. McMinn
Listed
March 7, 2014
P/E
-4.69
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$1.6M
Operating income
-$111M
EBITDA
-$101M
Net income
-$98.6M
EPS
-$5.03
Total assets
$263M
Total debt
$9.1M
Earnings yield
-21.34%

Revenue segmentation

By product (FY 2024)
By region (FY 2024)

No geographic segmentation.

Showing FY 2024

Price chart

20.1526.2532.3638.4644.56
NGNE 1D NASDAQ O24.42H24.42L23.32C23.57+0.02 (+0.08%)Vol30.73K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
NGNENeurogene Inc. Press release Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome Business Wire
NGNENeurogene Inc. Stock news Head-To-Head Comparison: Neurogene (NASDAQ:NGNE) & Applied Dna Sciences (NASDAQ:BNBX) Defense World
NGNENeurogene Inc. Stock news Bank of New York Mellon Corp Purchases New Position in Neurogene Inc. $NGNE Defense World
NGNENeurogene Inc. Press release Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference Business Wire
NGNENeurogene Inc. Press release Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
NGNENeurogene Inc. Stock news Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
NGNENeurogene Inc. Press release Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates Business Wire
NGNENeurogene Inc. Press release Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
NGNENeurogene Inc. Press release Neurogene Inc. Announces Pricing of $125 Million Public Offering Business Wire
NGNENeurogene Inc. Press release Neurogene Inc. Announces Proposed Public Offering Business Wire
NGNENeurogene Inc. Press release Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
NGNENeurogene Inc. Press release Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates Business Wire
NGNENeurogene Inc. Press release Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy Business Wire
NGNENeurogene Inc. Press release Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
NGNENeurogene Inc. Press release Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy Business Wire
NGNENeurogene Inc. Press release Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors Business Wire
NGNENeurogene Inc. Press release Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
NGNENeurogene Inc. Stock news Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $44.00 Defense World
NGNENeurogene Inc. Press release Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates Business Wire
NGNENeurogene Inc. Stock news Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference Defense World
See more
FAQ

Questions about Neurogene Inc.

What does Neurogene Inc. do?
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidates include NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome, and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
What is NGNE's market cap?
Neurogene Inc. (NGNE) is a listed stock with a live quote. The latest market cap on this page is $372M.
Where is Neurogene Inc. headquartered?
Neurogene Inc. is headquartered in New York City, NY.
How do I get NGNE news from the API?
Call GET /v1/news?tickers=NGNE. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does NGNE news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for NGNE, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the NGNE price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs